Nilotinib is a a tyrosine kinase inhibitor, which is targeted cancer therapy.
Tyrosine kinases are chemical messengers which stimulate cancer growth.
Nilotinib blocks the tyrosine kinase made by CML cells that have the abnormal Philadelphia chromosome - this was covered in the Pharmacology Dec 2017 tutorial.
Drug classification: P1S1S3